There is growing recognition that autophagy-related genes, including SQSTM1, may act as modifiers of neuromuscular disease or contribute to atypical clinical phenotypes, particularly in patients who lack common autoantibodies or clear structural abnormalities [13,14]. This evidence concerns the gene SQSTM1 and neuromuscular disease.